News Review: Apollo Investment Corporation (NASDAQ:AINV), Biostar Pharmaceuticals, Inc. (NASDAQ:BSPM)


Apollo Investment Corporation (NASDAQ:AINV)

Apollo Investment Corporation (NASDAQ:AINV) represented a move of -0.36 percent or $0.03 per share and closed its previous day trading session at $5.46. 875958 Shares were traded in the last trading session with an Average Volume of 1.09 Million Shares. The stock currently has a Market Capitalization of 1.23 Billion.

Apollo Investment Corporation is a closed-end investment company that has elected to be treated as a business development company under the Investment Company Act of 1940. The Company’s investment portfolio will be principally in middle-market private companies.

The stock traded between $5.30 and $6.82 over 1-Year time period showing its price to sales ratio of 4.67. Apollo Investment Corporation (NASDAQ:AINV) is currently showing an INCREASING volatility over a period of 10-Days while the 20-Days Volatility showing a INCREASING trend.

Right now, the stock has a 50-Day Simple Moving Average of $-4.88 and 200-Day Simple Moving Average of $-10.49. Its Price to Free Cash Flow is 7.42 and Price to Book of 0.83.

Analyst’s recommended the stock as 2.4 where 1 represents Strong Buy and 5 represents Sell.

In the last Quarter, Apollo Investment Corporation (NASDAQ:AINV) reported its Actual EPS of $0.16/share. The analysts offering Earnings Estimates for the company were believing that Apollo Investment Corporation could bring EPS of $0.15/share. The difference between Actual EPS and Estimated EPS was 0.01 Percent. Thus showing an Earnings Surprise of 6.7 Percent.

Biostar Pharmaceuticals, Inc. (NASDAQ:BSPM)

In the last trading session, Biostar Pharmaceuticals, Inc. (NASDAQ:BSPM) added its value by 3.59% closing at the price of $4.65. The stock currently has market capitalization of 11.24 Million, with average volume of 944.23 Million shares.

Beta is also a factor of measure of the relative volatility of a particular stock to the market. Currently Biostar Pharmaceuticals, Inc. (NASDAQ:BSPM) is showing beta of 1.17. This particular value of beta suggests that Biostar Pharmaceuticals, Inc. (NASDAQ:BSPM) has historically moved 117% for every 100% move in the benchmark, based on price level.

EPS is another important factor while making the decision of buying, selling or holding of particular share. Currently EPS for Biostar Pharmaceuticals, Inc. (NASDAQ:BSPM) is at $0.4.

The stock currently has RSI of 71.31. RSI is considered overbought when above 70 and oversold when below 30, currently the given RSI for the stock suggests that the stock is average and it has not entered in overbought or oversold territory.

BioStar Pharmaceuticals, Inc., through its wholly-owned subsidiary, Shaanxi Aoxing Pharmaceutical Co., Ltd., develops, manufactures and markets pharmaceutical and medical nutrient products for a variety of diseases and conditions. The Company’s most popular product is its Xin Ao Xing Oleanolic Acid Capsule, an over-the-counter medicine for chronic hepatitis B, a disease affecting approximately 10% of the Chinese population. In addition to its hepatitis product, Biostar manufactures two broad-based over-the-counter products, two prescription-based pharmaceuticals and ten nutrients. The Company has adopted international standards and is in the process of applying for three patents. It also operates an herbal medicine planting base which provides it with many of its needed materials at a significantly lower cost than purchasing from third parties, and eliminates most needs for transportation.

Biostar Pharmaceuticals, Inc. (NASDAQ:BSPM) topped its 52-week high price of $5.97 on 01/26/18 and 52-Week Low Price of $1.18 on 09/18/17. The Stock currently has P/E (price to earnings ttm) of 11.76 and Weekly volatility of 15.80% and monthly volatility of 24.74% respectively.